{"nctId":"NCT01406717","briefTitle":"Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus","startDateStruct":{"date":"2013-03-01"},"conditions":["Type 2 Diabetes Mellitus"],"count":360,"armGroups":[{"label":"SPIL1033","type":"EXPERIMENTAL","interventionNames":["Drug: SPIL1033"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"SPIL1033","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female subjects 20 years of age and older.\n* Established clinical diagnosis of type 2 diabetes mellitus treated with diet and exercise or anti-diabetic agents as monotherapy or combination therapy.\n* Weight stable: their weight should not have varied more than 10% of screening visit weight, within 6 months prior to screening visit.\n* Women of child bearing potential practicing an acceptable method of birth control as judged by the investigator(s); with a negative urine pregnancy test.\n* Willing to participate and give written informed consent.\n\nExclusion Criteria:\n\n* Previous exposure to exenatide (anti-exenatide antibodies at screening) or a glucagon-like peptide (GLP-1) analogue.\n* Used drugs for weight loss (for example, orlistat, sibutramine, phenylpropanolamine, rimonabant, or similar over-the-counter medications) within 3 months of screening.\n* Received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of trial entry.\n* Severe renal impairment (creatinine clearance \\<30 ml/min) or end stage renal disease.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to End of Study in Hemoglobin A1c (HbA1c)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.227","spread":"0.243"},{"groupId":"OG001","value":"-0.227","spread":"0.254"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to End of Study in Fasting Plasma Glucose (FPG)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":"9.78"},{"groupId":"OG001","value":"-5.42","spread":"10.21"}]}]}]},{"type":"PRIMARY","title":"Count and Percentage of Subjects Positive for Anti-exenatide Antibodies","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Count and Percentage of Subjects With Potentially Immune-related Treatment-emergent Adverse Events (TEAEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2hour Postprandial Glucose (2-h PPG)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.20","spread":"14.50"},{"groupId":"OG001","value":"-16.83","spread":"14.49"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Triglycerides","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.27","spread":"16.53"},{"groupId":"OG001","value":"8.39","spread":"16.53"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Low Density Lipoproteins","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.18","spread":"6.12"},{"groupId":"OG001","value":"0.15","spread":"6.12"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in High Density Lipoproteins","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.64","spread":"2.16"},{"groupId":"OG001","value":"0.62","spread":"2.16"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.708","spread":"0.468"},{"groupId":"OG001","value":"-0.792","spread":"0.467"}]}]}]},{"type":"SECONDARY","title":"Subjects Achieving Hemoglobin A1c (HbA1c) < 7%","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Very Low Density Lipoproteins","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.88","spread":"3.13"},{"groupId":"OG001","value":"1.55","spread":"3.13"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Cholesterol","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.89","spread":"7.40"},{"groupId":"OG001","value":"-0.11","spread":"7.40"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":180},"commonTop":["Hyperglycemia","Nausea","Dyslipidaemia","Hypoglycaemia","Headache"]}}}